Trials / Completed
CompletedNCT01300533
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
A Phase 1 Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Given by Intravenous Infusion to Patients With Advanced or Metastatic Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 58 (actual)
- Sponsor
- BIND Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this Phase 1 clinical research study is to find the highest safe dose of BIND-014 that can be given in the treatment of patients with advanced or metastatic cancer.
Detailed description
The study is designed to explore the safety, tolerability, pharmacokinetics and pharmacodynamics of BIND-014 and define a recommended Phase 2 dose of BIND-014. All cycles of therapy will consist of the patient taking BIND-014 intravenously once every three weeks or weekly for three out of four weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BIND-014 |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2013-09-01
- Completion
- 2016-02-01
- First posted
- 2011-02-21
- Last updated
- 2016-02-09
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01300533. Inclusion in this directory is not an endorsement.